ReviewCurrent cardiology reports2001
Pathophysiology and treatment of the dyslipidemia of insulin resistance.
Review in Current cardiology reports, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort).BMC dermatology · 2016Trial
- Modulation of Sirtuin-1 by Resveratrol as a Potential Therapy in Alleviating Metabolic Syndrome.Cell biochemistry and biophysics · 2026Review
- Characteristics of Dyslipidemia in Adults With Resistance to Thyroid Hormone β.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Article
- Dual Machine Learning Framework for Predicting Long-Term Glycemic Change and Prediabetes Risk in Young Taiwanese Men.Diagnostics (Basel, Switzerland) · 2025Article
- Therapeutic Potential of Infrared and Related Light Therapies in Metabolic Diseases.International journal of molecular sciences · 2025Review
- Article
- Association of niacin intake and metabolic dysfunction-associated steatotic liver disease: findings from National Health and Nutrition Examination Survey.BMC public health · 2024Article
- The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with type 2 diabetes mellitus: recent findings from NHANES 2007-2018.Lipids in health and disease · 2024Article
- Machine Learning Prediction of Prediabetes in a Young Male Chinese Cohort with 5.8-Year Follow-Up.Diagnostics (Basel, Switzerland) · 2024Article
- Cholesterol-metabolism, plant sterols, and long-term cognitive decline in older people - Effects of sex and APOEe4.iScience · 2024Article
- Association between Dyslipidemia and Glycated Hemoglobin in a Population-Based Study.Metabolites · 2024Article
- The efficacy of metformin for the treatment of psoriasis: a meta-analysis study.Postepy dermatologii i alergologii · 2023Review
- The Role of Lipids in the Regulation of Immune Responses.Nutrients · 2023Review
- Cluster analysis of Thai patients with newly diagnosed type 2 diabetes mellitus to predict disease progression and treatment outcomes : A prospective cohort study.BMJ open diabetes research & care · 2022Article
- Role of Beta Cell Function and Insulin Resistance in the Development of Gestational Diabetes Mellitus.Nutrients · 2022Article
- Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis.Cell death discovery · 2020Article
- Sex-Dependent Dyslipidemia and Neuro-Humoral Alterations Leading to Further Cardiovascular Risk in Juvenile Obesity.Frontiers in nutrition · 2020Article
- Association of insulin, C-peptide and blood lipid patterns in patients with impaired glucose regulation.BMC endocrine disorders · 2019Article
- Identifying adolescent metabolic syndrome using body mass index and waist circumference.Preventing chronic disease · 2008Article
- Sonographic fatty liver, overweight and ischemic heart disease.World journal of gastroenterology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin resistance, and the compensatory hyperinsulinemia that results, has been linked to a host of defects including glucose intolerance, diabetes, hypertension, dyslipidemia, endothelial dysfunction, impaired fibrinolysis, and subclinical inflammation. Patients with this metabolic syndrome have a markedly increased risk for the development of atherothrombotic cardiovascular disease. The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol. Management of this dyslipidemia typically involves a dual approach. Lifestyle modification is an essential component of any successful treatment plan, but alone is usually insufficient to correct these lipoprotein abnormalities. Medications that diminish insulin resistance and directly alter lipoproteins are also necessary in the majority of cases. Combinations of therapeutic agents are often required to optimize attainment of treatment goals.
Indexed as
Identifiers
11504579What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.